Bio-Rad Describes Detailed Neuroblastoma Study Using qPCR Analysis
News Aug 04, 2008
Bio-Rad Laboratories, Inc. has announced the availability of two bulletins (numbers 5713 and 5692) describing a major study demonstrating how real-time quantitative PCR (rt-qPCR) analysis provides method for evaluating the knockdown efficiency and functional consequences of RNAi-mediated gene silencing.
The study uses examples from neuroblastoma research conducted at Bio-Rad and by researchers at Ghent University, Belgium.
Real-time quantitative PCR is the method of choice for specific quantitation of nucleic acid sequences. Applications of this technology are numerous, both in molecular diagnostics and in virtually all fields of life sciences, including gene expression profiling, measurement of DNA copy number alterations, genotyping, mutation detection, pathogen detection, measurement of viral load, disease monitoring, and assessment of drug response.
Several ingredients are essential to the completion of an rt-qPCR assay, such as careful primer design and evaluation, template preparation, the use of a normalization strategy, and data analysis.
Bulletin 5713 describes the workflow steps needed for successful neuroblastoma experimentation, from experimental design to analysis of an rt-qPCR assay through careful attention to primer design and evaluation, template preparation, normalization strategy, and data analysis. Bulletin 5692 provides additional information on the experiments that contributed to research number 5713, including instruments, reagents, and procedures.
Future neuroblastoma studies are planned to evaluate results achieved using additional cell lines and varying combinations of multiple siLentMer™ siRNA duplexes, durations of effect, and concentrations of active siLentMer siRNA duplexes.
Genetic Diversity Helps Protect Against DiseaseNews
Why do populations have genetic diversity when 'Survival of the Fittest' suggests that only one gene pool should thrive? It's a question that is hard to answer experimentally. A new study looking at evolutionary change in real time in tiny fungal parasites may provide a solution.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE